[Customized pharmacotherapies in schizophrenia]

Area of Science:

• Pharmacogenetics
• Psychiatric Pharmacology
• Clinical Toxicology

Background:

• Predicting psychiatric medication efficacy and side effects solely on genetic information is challenging.
• Previous research emphasized analyzing pharmacokinetic and pharmacodynamic factors alongside genetics for depression treatment (e.g., fluvoxamine).
• Schizophrenia treatment goals are less defined, and genetic prediction studies for its effects are limited.

Purpose of the Study:

• To investigate the prediction of antipsychotic side effects, focusing on metabolic anomalies, QT prolongation, and hyperprolactinemia.
• To explore the relationship between genetic information and these quantifiable side effects.
• To identify specific characteristics of side effects that may influence genetic analysis.

Main Methods:

• Focus on quantifiable side effects: metabolic anomalies, QT prolongation, and hyperprolactinemia.
• Analysis of genetic information in conjunction with observed side effect characteristics.
• Exploration of potential influencing factors such as gender and time of administration.

Main Results:

• A gender difference was observed in glycolipid metabolic anomalies.
• Antipsychotics were found to particularly extend the QT interval during nighttime.
• Prolactin levels showed a temporary increase followed by a decline after antipsychotic administration.

Conclusions:

• Understanding the nuanced characteristics of psychiatric drug side effects is essential for effective genetic analysis.
• Genetic information may be underutilized if side effect complexities (e.g., gender, temporal patterns) are not considered.
• Further research is needed to integrate these complex side effect profiles with genetic data for improved treatment prediction.